StreetAlpha.app
Home › Stocks › SLDB

Solid Biosciences Inc. (SLDB)

Healthcare
$6.23
▼ −3.86%
LAST CLOSE · NOV 17

Solid Biosciences develops gene therapy candidates for rare neuromuscular and cardiac diseases, starting with Duchenne muscular dystrophy. It last closed at $6.23 on Nov 17, down 3.86% on the day. The average 12-month price target from 4 analysts is $21.00 (+237.1% from the last close), with a high of $26.00 and a low of $18.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).

AI Auto Pilots
Is SLDB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$215.3M
EPS (diluted)
−$1.76
Free cash flow
−$200.3M
Valuation
Market cap
$695.3M
111.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$126.0M
At Sep 30
Shareholder equity
$342.1M
Shares outstanding
111.6M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$72.2M−$72.2MFY2021FY2022: −$86.0M−$86.0MFY2022FY2023: −$96.0M−$96.0MFY2023FY2024: −$124.7M−$124.7MFY2024FY2025: −$174.3M−$174.3MFY2025

From SLDB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on SLDB in the past 90 days
Average 12-month target
$21.00
▲ 237.1% upside

Based on 4 analysts who set a price target on SLDB in the past 90 days. The average target is $21.00, with a high of $26.00 and a low of $18.00, compared with the last close of $6.23.

Low $18.00Avg $21.00High $26.00
Blue marker: last close $6.23
Highest target$26.00
Average target$21.00
Lowest target$18.00
Latest rating changes
UBSInitiated
Oct 15Buy$20
RBC CapitalInitiated
Sep 16Buy$18
Cantor FitzgeraldMaintained
Aug 27Buy$26
Truist SecuritiesMaintained
Aug 21Buy$20
HC Wainwright & Co.Maintained
Jun 3Buy$25
DateFirmActionRatingPrice target
Oct 15UBSInitiatedBuy$20
Sep 16RBC CapitalInitiatedBuy$18
Aug 27Cantor FitzgeraldMaintainedBuy$26
Aug 21Truist SecuritiesMaintainedBuy$20
Jun 3HC Wainwright & Co.MaintainedBuy$25
Loading…

Technical Analysis

SLDB · as of the Nov 17 close · updated after every close
Downtrend

The stock is 4% below its 20 day and 13% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the Pivot S1 at $6.05, and the nearest resistance the Pivot at $6.28.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 7.8%/day
Key levels
$11.4552 week high+83.8%
$8.18100 day average+31.3%
$7.68200 day average+23.3%
$7.0550 day average+13.2%
$6.58Swing high (Oct 21)+5.6%
$6.4820 day average+4.0%
$6.46Pivot R1+3.7%
$6.28Pivot+0.8%
$6.23Last close
$6.05Pivot S1−2.9%
$5.83Swing low (Nov 2)−6.4%
$4.1652 week low−33.2%
Indicators
RSI (14)43.94Middle of its rangeNeutral
MACD-0.04Above its signal lineBullish
Stochastic34.4Middle of its rangeNeutral
ADX (14)21.0Weak trend
Williams %R-80.3Oversold below −80, overbought above −20Oversold
CCI (20)-39.4Oversold below −100, overbought above 100Neutral
Rate of change−0.8%Change over 10 sessionsBearish
ATR (14)$0.49Typical daily range, 7.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SLDB

What happened before

See how SLDB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SLDB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SLDB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SLDB in the last 90 days.

Loading…

See today’s whale options flow across the market →

SLDB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●79 buying vs 69 selling
  • ▲Held by funds +3.9 pts
  • ●Funds holding +1
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding158157+0.6%
In funds' top 10330.0%
Held by funds106.5%102.6%+3.9 pts
New / increased25 / 5441 / 56−18.6%
Reduced / sold out46 / 2337 / 24+13.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SLDB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SLDB is in one of them and how their past SLDB trades turned out.

SLDB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SLDB in an article yet. Here's the latest on the wider market.

About Solid Biosciences

Solid Biosciences is a life sciences company based in Charlestown, Massachusetts, that develops gene therapy candidates for rare neuromuscular and cardiac diseases. Its lead candidate, SGT-003, is designed to treat Duchenne muscular dystrophy by delivering a gene that produces a smaller version of the dystrophin protein. The company is also developing candidates for Friedreich's ataxia and other genetic heart diseases. Its work is aimed at patients living with these rare conditions, many of whom have few treatment options.

Headquarters
Charlestown, MA